Prevention of perioperative renal failure

Anesthesia and Analgesia

Volumn 100, Issue 3 SUPPL., 2005, Pages 78-88

  Sladen, Robert N ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANARITIDE; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; CHLORPROMAZINE; CISPLATIN; CONTRAST MEDIUM; CYCLOSPORIN A; DEXTRAN; DILTIAZEM; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPEXAMINE; ENFLURANE; ETACRYNIC ACID; FENOLDOPAM; FLUORIDE; FUROSEMIDE; HALOPERIDOL; INDOMETACIN; INOTROPIC AGENT; KETOROLAC; LOOP DIURETIC AGENT; MANNITOL; MECLOFENAMIC ACID; METHOXYFLURANE; METOCLOPRAMIDE; METOLAZONE; MILRINONE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; RECOMBINANT INTERLEUKIN 2; SODIUM CHLORIDE; TACROLIMUS; TORASEMIDE; URODILATIN; VANCOMYCIN; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ALGORITHM; CLINICAL TRIAL; CONFERENCE PAPER; CRUSH SYNDROME; DEHYDRATION; DIURETIC THERAPY; DRUG INFUSION; DRUG WITHDRAWAL; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYDRATION; HYPOTENSION; HYPOVOLEMIA; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY PERFUSION; LIVER FAILURE; LUNG EDEMA; NEPHROTOXICITY; NONHUMAN; OLIGURIA; OTOTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PRERENAL SYNDROME; PRIORITY JOURNAL; RESUSCITATION; RISK FACTOR; SEPSIS; TACHYCARDIA; URINE FLOW RATE;

EID: 17144382850     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (97)

1. Dishart MK, Kellum JA. An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. Drugs 2000;59:79-91.
2. Alpert RA, Roizen MF, Hamilton WK, et al. Intraoperative urinary output does not predict postoperative renal function in patients undergoing abdominal aortic revascularization. Surgery 1984;95:707.
3. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. N Engl J Med 1997;336:828-34.
4. Arendshorst WJ, Finn WF, Gottschalk CW. Pathogenesis of acute renal failure following temporary renal ischemia in the rat. Circ Res 1975;37:558.
5. Wilkes BM, Mailloux LU. Acute renal failure: pathogenesis and prevention. Am J Med 1986;80:1129-36.
6. Myers B, Chui F, Hilberman M, Michaels A. Transtubular leakage of glomerular filtrate in human acute renal failure. Am J Physiol 1979;237:F319-25.
7. Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986;314:97-105.
8. Butkus DE. Post traumatic acute renal failure in combat casualties: a historical review. Milit Med 1984;149:117-24.
9. Guly UM, Turney JH. Post-traumatic acute renal failure, 1956-1988. Clin Nephrol 1990;34:79-83.
10. Shin B, MacKenzie CF, McAslan TC, et al. Postoperative renal failure in trauma patients. Anesthesiology 1979;51:218-221.
11. Gorfinkel HJ, Szidon JP, Hirsch LJ, et al. Renal performance in experimental cardiogenic shock. Am J Physiol 1972;222:1260-8.
12. Laragh J. Atrial natriuretic hormone, the renin-angiotensin axis, and blood-pressure electrolyte homeostasis. N Engl J Med 1985;313:1330-40.
13. Maack T, Camargo MJF, Kleinert HD, et al. Atrial natriuretic factor: structure and functional properties. Kidney Int 1985;27:607-15.
14. Brezis M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med 1995;332:647-55.
15. Wardle N. Acute renal failure in the 1980s: the importance of septic shock and of endotoxemia. Nephron 1982;30:193-200.
16. Zager RA. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis 1992;20:223-30.
17. Wetzels JF, Burke TJ, Schrier RW. Prevention and attenuation of acute renal failure. Curr Opin Nephrol Hypertens 1992;1:133-40.
18. Clive D, Stoff J. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
19. Kunzendorf U, Walz G, Brockmoeller J, et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 1991;52:280-4.
20. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney Int 1992;Suppl 36:87-93.
21. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency or both: a prospective, controlled study. N Engl J Med 1989;320:143.
22. Eisenberg RL, Bank WO, Hedgecock MW. Renal failure after major angiography can be avoided with hydration. Am J Radiol 1981;136:859.
23. Sladen RN: Perioperative renal protection. In: Murray MJ, Coursin DB, Pearl RG, Prough DS, eds. Critical care medicine: perioperative management. New York: Raven Press, 1996:551-64.
24. Desjars PH, Pinaud M, Bugnon D, et al. Norepinephrine has no deleterious renal effects in human septic shock. Crit Care Med 1989;17:426-9.
25. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989;256:F274-8.
26. Brezis M, Rosen S, Epstein F. The pathophysiologic implications of medullary hypoxia. Am J Kidney Dis 1989;13:253-8.
27. Haywood GA, Tighe D, Moss R, et al. Goal directed therapy with dobutamine in a porcine model of septic shock: effects on systemic and renal oxygen transport. Postgrad Med J 1991;67(S1):S36.
28. Ron D, Taitelman U, Michaelson M, et al. Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med 1984;144:277.
29. Paul MD, Mazer CD, Byrick RJ, et al. Influence of mannitol and dopamine on renal function during elective infrarenal aortic cross-clamping in man. Am J Nephrol 1986;6:427-34.
30. Parks RW, Diamond T, McCrory DC, et al. Prospective study of postoperative renal function in obstructive jaundice and the effect of perioperative dopamine. Br J Surg 1994;81:437-9.
31. Plusa SM, Clark NW. Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a comparison of mannitol-induced diuresis and oral sodium taurocholate. J Roy Coll Surg Edin 1991;36:303-5.
32. Brater DC. Diuretic resistance: mechanisms and therapeutic strategies. Cardiology 1994;84(suppl 2):57-67.
33. Sjostrom PA, Odlind BG, Beermann BA, Hammarlund Udenaes M. On the mechanism of acute tolerance to furosemide diuresis. Scand J Urol Nephrol 1988;22:133-40.
34. Bryan AG, Bolsin SN, Vianna PTG, Haloush H. Modification of the diuretic and natriuretic effects of a dopamine infusion by fluid loading in preoperative cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9:158-63.
35. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996;30:229-49.
36. Rose HJ, O'Malley K, Pruitt AW. Depression of renal clearance of furosemide in man by azotemia. Clin Pharmacol Ther 1976;21:141-6.
37. Knauf H, Mutschler E. Functional state of the nephron and diuretic dose-response: rationale for low-dose combination therapy. Cardiology 1994;84(suppl 2):18-26.
38. Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987;32:198-203.
39. Copeland JG, Campbell DW, Plachetka JR, et al. Diuresis with continuous infusion of furosemide after cardiac surgery. Am J Surg 1983;146:796-9.
40. Lawson DH, Gray JMB, Henry DA, Tilstone WJ. Continuous infusion of frusemide in refractory oedema. BMJ 1978;2:476.
41. van Meyel JJ, Smits P, Russel FG, et al. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin Pharmacol Ther 1992;51:440-4.
42. Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991;115:360-6.
43. Wilson NJ, Adderley RJ, McEniery JA. Supraventricular tachycardia associated with continuous furosemide infusion. Can J Anaesth 1991;8:502-5.
44. Behnia R, Koushanpour E, Brunner EA. Effects of hyperosmotic mannitol infusion on hemodynamics of dog kidney. Anesth Analg 1996;82:902.
45. Ip-Yam PC, Murphy S, Baines M, et al. Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth Analg 1994;78:842-7.
46. Pass L, Eberhart R, Brown J, et al. The effect of mannitol and dopamine on the renal response to thoracic aortic cross-clamping. J Thorac Cardiovasc Surg 1988;95:608-12.
47. Myers BD, Miller DC, Mehigan JT, et al. Nature of the renal injury following total renal ischemia in man. J Clin Invest 1984;73:329-41.
48. Brezis M, Rosen S, Silva P, et al. Transport activity modifies thick ascending limb damage in the isolated perfused kidney. Kidney Int 1984;25:65.
49. Anderson R, Linas S, Berns A, et al. Nonoliguric acute renal failure. N Engl J Med 1977;296:1134-7.
50. Kleinknecht D, Ganeval D, Gonzalez-Duque LA, et al. Furosemide in acute oliguric renal failure: a controlled trial. Nephron 1976;17:51.
51. Brown C, Ogg C, Cameron J. High dose furosemide in acute renal failure: a controlled trial. Clin Nephrol 1981;15:90-6.
52. Lokhandwala MF, Amenta F. Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 1991;5:3023-30.
53. Burton CJ, Tomson CR. Can the use of low-dose dopamine for treatment of acute renal failure be justified? Postgrad Med J 1999;75:269-74.
54. MacGregor DA, Smith TE, Prielipp RC, et al. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 2000;92:338-46.
55. Bailey JM. Dopamine: one size does not fit all. Anesthesiology 2000;92:303-5.
56. Davis RF, Lappas DG, Kirklin JK, et al. Acute oliguria after cardiopulmonary bypass: renal functional improvement with low-dose dopamine infusion. Crit Care Med 1982;10:852-6.
57. Costa P, Ottino GM, Matani A, et al. Low-dose dopamine during cardiopulmonary bypass in patients with renal dysfunction. J Cardiothoracic Anesth 1990;4:469-73.
58. Swygert TH, Roberts LC, Valek TR, et al. Effect of intraoperative low-dose dopamine on renal function in liver transplant recipients. Anesthesiology 1991;75:571-6.
59. De los Angeles A, Bacquero A, Bannett A, Raja R. Dopamine and furosemide infusion for prevention of post transplant oliguric renal failure. Kidney Int 1985;27:339-44.
60. Schaer GL, Fink MP, Parrillo JE. Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with combination pressor therapy. Crit Care Med 1985;13:492-6.
61. Lherm T, Troche G, Rossignol M, et al. Renal effects of low-dose dopamine in patients with sepsis syndrome or septic shock treated with catecholamines. Intensive Care Med 1996;22:213-9.
62. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-43.
63. Duke GJ, Briedes JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med 1994;22:1919-25.
64. Flancbaum L, Choban PS, Dasta JF. Quantitative effects of low-dose dopamine on urine output in oliguric surgical intensive care unit patients. Crit Care Med 1994;22:61-8.
65. Schwartz LB, Gewertz GL. The renal response to low-dose dopamine. J Surg Res 1988;45:574-88.
66. Ter Wee PM, Smit AJ, Rosman JB, et al. Effect of intravenous infusion of low-dose dopamine on renal function in normal individuals and in patients with renal disease. Am J Nephrol 1986;6:42-6.
67. Chiolero R, Borgeta A, Fisher A. Postoperative arrhythmias and risk factors after open heart surgery. Thorac Cardiovasc Surg 1991;39:81-4.
68. Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs 1997;54:634-50.
69. Murphy MB, McCoy CE, Weber RR, et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine-1 agonist fenoldopam. Circulation 1987;76:1312-8.
70. Oparil S, Aronson S, Deeb GM, Epstein M, et al. Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens 1999;12:653-64.
71. Panacek EA, Bednarczyk EM, Dunbar LM, et al. Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Fenoldopam Study Group. Acta Emergency Medicina 1995;2:959-65.
72. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998;31:743-55.
73. Brooks DP, DePalma PD, Cyronak MJ, et al. Pharmacology of SK&F R-105058 and R-106114, N-ethyl carbamate ester pro-drugs of fenoldopam. Pharmacology 1990;41:299-308.
74. Garwood S, Davis E, Hines RL. Fenoldopam: an effective renal preservation agent in cardiac surgery? Anesthesiology 1999;91: A154.
75. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
76. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290:2284-91.
77. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
78. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
79. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
80. Atanasova I, Girchev R, Dimitrov D, et al. Atrial natriuretic peptide and dopamine in a dog model of acute renal ischemia. Acta Physiol Hung 1994;82:75-85.
81. Seki G, Suzuki K, Nonaka T, et al. Effects of atrial natriuretic peptide on glycerol induced acute renal failure in the rat. Japan Heart J 1992;33:383-93.
82. Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994;45:1731-8.
83. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000;36:767-74.
84. Kelleher SP, Robinette JB, Miller F, Conger JD. Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure. Kidney Int 1987;31:725-30.
85. Mills RM, LeJemtel TH, Horton DF, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-62.
86. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001;7:92-100.
87. Mackay JH, Feerick AE, Woodson LC, et al. Increasing organ blood flow during cardiopulmonary bypass in pigs: comparison of dopamine and perfusion pressure. Crit Care Med 1995;23:1090-8.
88. Conger JD, Hammond WS. Renal vasculature and ischemic injury. Ren Fail 1992;14:307-10.
89. Cumming AD, Driedger AA, McDonald JW, et al. Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 1988;11:23-32.
90. Badr KF. Sepsis-associated renal vasoconstriction: potential targets for future therapy. Am J Kidney Dis 1992;20:207-13.
91. Hesselvik JF, Brodin B. Low-dose norepinephrine in patients with septic shock and oliguria: effecis on afterload, urine flow and oxygen transport. Crit Care Med 1989;17:179-180.
92. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-82.
93. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
94. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95.
95. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
96. Edwards RM, Rizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol 1989;256:F526-34.
97. Argenziano M, Choudri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997;96[suppl II]:II-286-90.